{"disease":{"id":"autosomal-recessive-polycystic-kidney-disease","name":"autosomal recessive polycystic kidney disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT07201025","title":"Imaging Assessments of ARPKD Kidney Disease Progression","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT06601829","title":"Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT04786574","title":"A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}